{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:28:36Z","timestamp":1793780916463,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seroepidemiology, or measuring antibodies to pathogens to estimate population-level exposure, can provide useful public health data. The tests used, however, often lack sufficient validation data due to absence of a gold standard. For many pathogens, serum antibodies can be detected long after resolution of infection, but infection status is often used as a gold standard for antibody positivity. To ensure that recently developed antibody tests for seroepidemiology of <jats:italic>Chlamydia trachomatis<\/jats:italic> (Ct), the causative agent of urogenital chlamydia and the blinding eye disease trachoma, have high performance, we generated a chimeric antibody to the immunodominant Ct antigen Pgp3. Two clones were selected to evaluate the test performance of three assays to measure antibodies to Pgp3: multiplex bead assay (MBA), enzyme-linked immunosorbent assay (ELISA), and lateral flow assay (LFA). Overall, each assay demonstrated high accuracy and precision when tested using either clone, and the clones were stable when stored at \u2212\u200920\u00a0\u00b0C and 4\u00a0\u00b0C for almost 2\u00a0years. The limit of detection was similar for MBA and LFA, but almost a log-fold higher (i.e. less sensitive) using ELISA. Overall, the chimeric antibodies represent stable control reagents for tests with robust performance and will facilitate deployment of these tests to other laboratories.<\/jats:p>","DOI":"10.1038\/s41598-023-33834-4","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:02:09Z","timestamp":1683219729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of immunoassays for the Chlamydia trachomatis antigen Pgp3 using a chimeric monoclonal antibody"],"prefix":"10.1038","volume":"13","author":[{"given":"Brook","family":"Goodhew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gwyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"9","key":"33834_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008316","volume":"14","author":"DL Martin","year":"2020","unstructured":"Martin, D. L. et al. The use of serology for trachoma surveillance: Current status and priorities for future investigation. PLoS Negl. Trop. Dis. 14(9), e0008316 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"33834_CR2","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1016\/S1473-3099(18)30159-2","volume":"18","author":"SC Woodhall","year":"2018","unstructured":"Woodhall, S. C. et al. Advancing the public health applications of Chlamydia trachomatis serology. Lancet Infect. Dis. 18(12), e399\u2013e407 (2018).","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"33834_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001873","volume":"6","author":"EB Goodhew","year":"2012","unstructured":"Goodhew, E. B. et al. CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl. Trop. Dis. 6(11), e1873 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"33834_CR4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4269\/ajtmh.17-0292","volume":"97","author":"S Gwyn","year":"2017","unstructured":"Gwyn, S. et al. Comparison of platforms for testing antibody responses against the Chlamydia trachomatis antigen Pgp3. Am. J. Trop. Med. Hyg. 97(6), 1662\u20131668 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"33834_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jim.2016.05.008","volume":"435","author":"S Gwyn","year":"2016","unstructured":"Gwyn, S. et al. Lateral flow-based antibody testing for Chlamydia trachomatis. J. Immunol. Methods 435, 27\u201331 (2016).","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"33834_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2018.11.001","volume":"93","author":"S Gwyn","year":"2019","unstructured":"Gwyn, S., Mkocha, H., Randall, J. M., Kasubi, M. & Martin, D. L. Optimization of a rapid test for antibodies to the Chlamydia trachomatis antigen Pgp3. Diagn. Microbiol. Infect. Dis. 93(4), 293\u2013298 (2019).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"10","key":"33834_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007749","volume":"13","author":"SE Burr","year":"2019","unstructured":"Burr, S. E. et al. Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: Cross-sectional surveys in six evaluation units. PLoS Negl. Trop. Dis. 13(10), e0007749 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"33834_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.12688\/wellcomeopenres.13423.2","volume":"3","author":"R Butcher","year":"2018","unstructured":"Butcher, R. et al. Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis. Wellcome Open Res. 3, 14 (2018).","journal-title":"Wellcome Open Res."},{"issue":"9","key":"33834_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005863","volume":"11","author":"A Cama","year":"2017","unstructured":"Cama, A. et al. Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. PLoS Negl. Trop. Dis. 11(9), e0005863 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"33834_CR10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.4269\/ajtmh.21-0124","volume":"104","author":"GM Cooley","year":"2021","unstructured":"Cooley, G. M. et al. No serological evidence of trachoma or yaws among residents of registered camps and makeshift settlements in Cox\u2019s Bazar, Bangladesh. Am. J. Trop. Med. Hyg. 104(6), 2031\u20132037 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5","key":"33834_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4269\/ajtmh.21-0541","volume":"105","author":"S Gwyn","year":"2021","unstructured":"Gwyn, S. et al. The performance of immunoassays to measure antibodies to the Chlamydia trachomatis antigen Pgp3 in different epidemiological settings for trachoma. Am. J. Trop. Med. Hyg. 105(5), 1362\u20131367 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5","key":"33834_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.4269\/ajtmh.21-1140","volume":"106","author":"J Hammou","year":"2022","unstructured":"Hammou, J. et al. Post-validation survey in two districts of morocco after the elimination of trachoma as a public health problem. Am. J. Trop. Med. Hyg. 106(5), 1370 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"33834_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010275","volume":"16","author":"KD Lynch","year":"2022","unstructured":"Lynch, K. D. et al. A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru. PLoS Negl. Trop. Dis. 16(4), e0010275 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"3","key":"33834_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cid\/ciaa042","volume":"72","author":"CK Macleod","year":"2020","unstructured":"Macleod, C. K., Butcher, R., Javati, S., Gwyn, S., Jonduo, M., Abdad, M. Y. et al. Trachoma, anti-Pgp3 serology and ocular Chlamydia trachomatis infection in Papua New Guinea. Clin. Infect. Dis. 72(3), 423\u2013430 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"33834_CR15","doi-asserted-by":"publisher","first-page":"15040","DOI":"10.1038\/s41598-017-15056-7","volume":"7","author":"SJ Migchelsen","year":"2017","unstructured":"Migchelsen, S. J. et al. Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia. Sci. Rep. 7(1), 15040 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"33834_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4269\/ajtmh.20-0777","volume":"104","author":"SD Nash","year":"2021","unstructured":"Nash, S. D. et al. Population-based prevalence of Chlamydia trachomatis infection and antibodies in four districts with varying levels of trachoma endemicity in Amhara, Ethiopia. Am. J. Trop. Med. Hyg. 104(1), 207\u2013215 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"33834_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004462","volume":"10","author":"BP Pant","year":"2016","unstructured":"Pant, B. P. et al. Control of trachoma from Achham District, Nepal: A cross-sectional study from the Nepal National Trachoma Program. PLoS Negl. Trop. Dis. 10(2), e0004462 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"33834_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007027","volume":"12","author":"LG Senyonjo","year":"2018","unstructured":"Senyonjo, L. G. et al. Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem. PLoS Negl. Trop. Dis. 12(12), e0007027 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"33834_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009457","volume":"15","author":"Y Chan","year":"2021","unstructured":"Chan, Y. et al. Determining seropositivity-A review of approaches to define population seroprevalence when using multiplex bead assays to assess burden of tropical diseases. PLoS Negl. Trop. Dis. 15(6), e0009457 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"33834_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005230","volume":"11","author":"SJ Migchelsen","year":"2017","unstructured":"Migchelsen, S. J. et al. Defining seropositivity thresholds for use in trachoma elimination studies. PLoS Negl. Trop. Dis. 11(1), e0005230 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"33834_CR21","doi-asserted-by":"publisher","first-page":"9682","DOI":"10.1038\/s41598-021-88809-0","volume":"11","author":"AP Chapman","year":"2021","unstructured":"Chapman, A. P. et al. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies. Sci. Rep. 11(1), 9682 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"33834_CR22","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1038\/s41598-021-86639-8","volume":"11","author":"S Gwyn","year":"2021","unstructured":"Gwyn, S. et al. Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo. Sci. Rep. 11(1), 7225 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"33834_CR23","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1038\/s41598-018-22708-9","volume":"8","author":"RE Wiegand","year":"2018","unstructured":"Wiegand, R. E. et al. Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. Sci. Rep. 8(1), 4232 (2018).","journal-title":"Sci. Rep."},{"issue":"1","key":"33834_CR24","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1038\/s41467-018-07852-0","volume":"9","author":"A Pinsent","year":"2018","unstructured":"Pinsent, A. et al. The utility of serology for elimination surveillance of trachoma. Nat. Commun. 9(1), 5444 (2018).","journal-title":"Nat. Commun."},{"issue":"8","key":"33834_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/cid\/ciab506","volume":"73","author":"GE Anyalechi","year":"2021","unstructured":"Anyalechi, G. E. et al. High plasmid gene protein 3 (Pgp3) Chlamydia trachomatis seropositivity, pelvic inflammatory disease, and infertility among women, national health and nutrition examination survey, United States, 2013\u20132016. Clin. Infect. Dis. 73(8), 1507\u20131516 (2021).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33834-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:05:24Z","timestamp":1683219924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33834-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33834"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33834-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7281"}}